









Markets
/
Stocks
/
nasdaq-bntc
/

Benitec Biopharma Inc

BNTC

13.990USD

+0.290+2.12%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

357.39MMarket Cap

LossP/E TTM



Benitec Biopharma Inc

13.990

+0.290+2.12%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

44 / 506

Overall Ranking

132 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Strong Buy

Current Rating

26.167

Target Price

+91.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 22.86.

Overvalued

The company’s latest PE is 17.19, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 23.43M shares, increasing 11.88% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 969.17K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.79.

Financial Health

Currency: USD Updated：2025-09-18

The company's current financial score is 6.60, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.60

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.52

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.71

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 16.83, which is -100.92% below the recent high of -0.15 and 104.46% above the recent low of -0.75.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 44/506

No Data

Earnings Forecast

Currency: USD Updated：2025-09-18

The company’s current earnings forecast score is 9.00, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Benitec Biopharma Inc is 28.50, with a high of 30.00 and a low of 20.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Strong Buy

Current Rating

26.167

Target Price

+91.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Benitec Biopharma Inc

BNTC

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-18

The company’s current price momentum score is 8.92, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 14.55 and the support level at 12.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.92

Change

0.2

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.028

Neutral

RSI(14)

59.341

Neutral

STOCH(KDJ)(9,3,3)

64.658

Buy

ATR(14)

0.560

High Vlolatility

CCI(14)

96.106

Neutral

Williams %R

20.875

Buy

TRIX(12,20)

0.496

Sell

StochRSI(14)

97.094

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

13.832

Buy

MA10

13.822

Buy

MA20

13.535

Buy

MA50

12.581

Buy

MA100

13.414

Buy

MA200

12.774

Buy

Institutional Confidence

Currency: USD Updated：2025-09-18

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 89.26%, representing a quarter-over-quarter increase of 1.11%. The largest institutional shareholder is The Vanguard, holding a total of 969.17K shares, representing 3.69% of shares outstanding, with 188.60% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Suvretta Capital Management, LLC

9.88M

+10.23%

Janus Henderson Investors

2.92M

+11.56%

Franklin Advisers, Inc.

2.86M

-2.67%

Adage Capital Management, L.P.

1.97M

HBM Partners AG

1.04M

+23.80%

The Vanguard Group, Inc.

Star Investors

327.03K

+9.00%

Nantahala Capital Management, LLC

838.10K

Nemean Asset Management, LLC

746.32K

+659.98%

BlackRock Institutional Trust Company, N.A.

183.89K

+6.16%

INFINITUM ASSET MANAGEMENT, LLC

475.00K

+126.19%

Risk Assessment

Currency: USD Updated：2025-09-18

The company’s current risk assessment score is 4.86, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.40. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.